Technivie, from AbbVie, is a combination of ombitasvir, paritaprevir and ritonavir. The drug is designed for use with ribavarin for adult HCV patients with genotype 4, according to the report. All patients who used Technivie with ribavarin experienced sustained virologic response at 12 weeks, compared to 91 percent of patients who used the drug without ribavarin, according to the report.
Daklinza, from Bristol-Myers Squibb, also received FDA approval. The drug was cleared for use with Sovaldi from Gilead Sciences for the treatment of HCV genotype 3, according to the report. Sustained virologic response at 12-weeks was achieved by 98 percent of patients with no cirrhosis and in 58 percent of patients with cirrhosis.
More articles on gastroenterology:
Payment landscape forecast: 3 gastroenterologists consider the possibility of colonoscopy reimbursement cuts
170 GI physicians making headlines in 2015 so far
Dr. Gary Reiss: The new frontier in GERD & Barrett’s esophagus treatment
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
